BIO vs DHR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIO and DHR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIO and DHR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bio-Rad Laboratories designs and sells laboratory instruments, consumables, and reagents across two segments. Life Science supplies tools for molecular biology, protein analysis, and genomics, including its droplet digital PCR (ddPCR) systems, real-time PCR, electrophoresis, imaging, and process chromatography products. Clinical Diagnostics sells the workflows routine hospital and reference labs rely on: quality-control and data-management systems, blood typing and immunohematology, diabetes monitoring, and specialty assays. Trailing revenue runs around $2.58 billion, and the business is known for recurring consumables attached to a large installed base of instruments.

Full BIO guide

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BIO drivers: Sartorius stake and activist pressure; Digital PCR and Life Science recovery.
• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The 2026 outlook was cut, with currency-neutral revenue guided to roughly a 3% decline to modest growth and operating margin trimmed toward 10% to 12%. For DHR, valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s), leaving little room for disappointment.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIO if you believe its drivers more; DHR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIO and DHR guides.

BIO. At roughly $309 per share and an $8.5 billion market cap, the market values Bio-Rad's Sartorius stake at close to its entire capitalization, implying it assigns little value to the operating business. Trailing earnings are volatile because non-cash marks on the Sartorius holding flow through GAAP results, so headline EPS and P/E can be misleading. The activist thesis rests on that gap between the sum of the parts and the traded value.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, while adjusted EPS grew faster on margins and buybacks. The stock has typically carried a premium valuation, with a trailing P/E in the mid-30s to mid-40s and a forward P/E closer to the low 20s as estimates rise. Figures are approximate and as of JULY 2026.

Headline figures (approximate, July 2026): BIO shows revenue (ttm) ~$2.58B, q1 2026 revenue ~$592M, q1 2026 non-gaap eps ~$1.89, market cap ~$8.5B; DHR shows revenue (fy2025) ~$24.6B, adj. diluted eps (fy2025) ~$7.80, free cash flow (fy2025) ~$5.3B, 2026 adj. eps guidance ~$8.35 to $8.55.

BIO and DHR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIO and DHR exposure against your real portfolio. It is not an investment adviser.